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Nitrogen, oxygen and sulfur containing compounds are the
most common heterocycles which serve as the core component
of a large number of biochemical materials which are essential
to life such as nucleic acids. Oxadiazoles are used as support
on which pharmacophores are placed to provide potent and
selective medicines (Somani and Shirodkar, 2009). During
the past few years, considerable evidence has been accumu-
lated that demonstrates the efﬁcacy of 1,3,4-oxadiazoles
including insecticidal, analgesic, diuretic, CNS depressant,
antiviral, herbicidal, antihypertensive, pesticidal activities and
these are cited in the literature (Deshmukh et al., 2011).
Oxadiazoles also possess antitubercular (Rane et al., 2012),
antimalarial (Mohan et al., 2004), antileishmanial (Rastogi
et al., 2006) and anticancer (Bondock et al., 2012) activities.
The 1,2,4-triazole derivatives possess a broad spectrum of
activities including antimalarial, anticancer and antitubercular
(Husain et al., 2012; Pattan et al., 2012) and also have a wide
range of therapeutic properties like analgesic (Almasirad et al.,
2011), insecticidal (Tirlapur and Tadmalle, 2011), hypoglyce-
mic (Nath et al., 2011), antiparasitic, herbicidal (Wang et al.,
2011) and plant growth activities (Aggarwal et al., 2011).
The 1,2,4-triazole nucleus is extensively used in medicines
(Aytac¸ et al., 2009). Due to ambidentate nucleophilic centers
i.e. mercapto and amino groups, the 4-amino-1,2,4-triazol-3-
thiones can be considered as excellent starting materials for
the synthesis of triazolothiadiazines. The substituted 1,2,4-
triazolo[3,4-b]-1,3,4-thiadiazine derivatives have been reported
to possess antimicrobial activity mainly due to N–C–S linkage
in the skeleton of triazolothiadiazine and also possess antican-
cer activity (Altintop et al., 2011; Badr and Barwa, 2011;
Mohammad et al., 2012; Prakash et al., 2011). These bihetero-
cyclic triazolothiadiazine derivatives also possess a broad spec-
trum of pharmacological activities (El-Shehry et al., 2010;
Kumar et al., 2010). The literature survey (Lamani and
Kotresh, 2010; Mohsen, 2012) reveals that there are many
examples of triazole fused with pyridines, pyridazines, pyrimi-
dines, pyrazines and triazines but triazolothiadiazines are not
very common moieties.
Earlier works (Sharma et al., 2011; Shalini et al., 2011)
showed that these heterocycles were synthesized from different
substituted carboxylic acids and hydrazides (other than long
chain alkenyl/hydroxyalkenyl hydrazides). Literature survey
(Srivastava et al., 2010) also reveals that a minor change in
the structure of 1,3,4-oxadiazoles, 1,2,4-triazoles and 1,2,
4-triazolo[3,4-b]-1,3,4-thiadiazines can lead to quantitative
and qualitative changes in biological activity. Recently (Jubie
et al., 2012), stearic acid (a saturated FA) analogs having
1,3,4-oxadiazole, 1,2,4-triazole and 1,2,4-triazolo-[3,4-b]1,3,
4-thiadiazole were reported as antidepressant and antimicro-
bial agents. Also, the usage of FAs shows an increasing trend
in the treatment of neuropsychological disorders such asd, A. et al., Synthesis and anticance
b]-1,3,4-thiadiazine derivatives. Adepression and schizophrenia (Sinclair et al., 2007; Yamima
and Belmaker, 2009). Despite this, some of the FAs have been
found to play a regulatory role in tumor growth progression
and were reported as effective anticancer agents (Khan et al.,
2011). Keeping in view the signiﬁcance, the aforementioned
facts of long chain alkenyl/hydroxyalkenyl carboxylic acids
as potential pharmacophores and in continuation of earlier re-
search work in our laboratory on the synthesis of novel series
of biologically active heterocyclic derivatives of FAs (Farshori
et al., 2011), we herein report the synthesis of three different
novel series of biologically important heterocyclic FA analogs.
And evaluate in vitro anticancer activity against three different
human cancer cell lines and normal human cells (PBMCs). The
salient features of the procedure described here are taking
short reaction time, not requiring elevated temperatures, the
use of cheap reagents and easily available starting materials.
2. Experimental protocol
2.1. Materials and methods
(Z)-octadec-9-enoic acid (purity, 97%) and undec-10-enoic
acid (purity, 98%) were purchased from Fluka chemicals (Swit-
zerland). (9Z, 12R)-12-hydroxyoctadec-9-enoic acid (Ricinolic)
and (9R, 12Z)-9-hydroxyoctadec-12-enoic acid (Isoricinolic)
were isolated from the natural sources i.e. from Ricinus commu-
nis andWrightia tinctoria seed oils respectively, following Gun-
stone’s partition procedure (Gunstone, 1954), general grade
(GR) of solvents was used for the extraction purposes. Hydro-
xy FAs were puriﬁed by column chromatography and charac-
terized by the spectral data. FA esters were prepared by
reﬂuxing the FAs in methanol in the presence of catalytic
amount of concentrated sulfuric acid. Long chain alkenyl/
hydroxyalkenyl hydrazide was used as starting material which
was previously synthesized in our laboratory. All the products
were puriﬁed by column chromatography. When required, sol-
vents were dried and distilled before use. Carbon disulﬁde,
potassium hydroxide, phenacyl bromide, hydrazine hydrate
were purchased from Merck, Mumbai, India. Thin layer chro-
matography (TLC) was performed on glass plates (20 · 5 cm)
with a layer of silica gel G (Merck, Mumbai, India, 0.55 mm
thickness). Developing solvents used were the mixture of petro-
leum ether-diethyl ether-acetic acid (75:25:1; v/v). Silica gel
(Merck, Mumbai, India, 60–120 mesh) was used for carrying
column chromatography. IR spectra were obtained on Shima-
dzu 8201 PC FT-IR using KBr Pellet with absorption given in
cm1. 1H NMR spectra were recorded with Bruker DRX 400
Spectrometer (400 MHz) in CDCl3, using TMS as internal
standard. Chemical shifts (d) are quoted in ppm and coupling
constants (J) are given in Hz. 13C NMR spectra were recorded
with Bruker, DRX 400 Spectrometer in CDCl3 (d= 77.00).
Mass spectra were recorded on JEOL-SX 102/DA-600 Mass
Spectrometer.r activity of long chain substituted 1,3,4-oxadiazol-2-thione, 1,2,4-tria-
rabian Journal of Chemistry (2014), http://dx.doi.org/10.1016/
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2.2.1. Synthesis of novel series of 5-long chain alkenyl/
hydroxyalkenyl-1,3-4-oxadiazol-2-thiones, 2(a–d)
A mixture of 0.01 mol of long chain alkenyl/hydroxyalkenyl
hydrazide (Rauf et al., 2007) 1(a–d), 0.01 mol of potassium
hydroxide and 10 mL of carbon disulﬁde was reﬂuxed
(80–90 C) in 50 mL ethanol for 8 h. The reaction mixture
was concentrated on water bath, then cooled to room temper-
ature, acidiﬁed with dil. HCl at 0 C and the solid product was
separated out. After that the product was ﬁltered and washed
with cold water. The solid products 2(a–d) were then air dried.
Further, the products 2(a–d) were puriﬁed by silica gel column
chromatography with petroleum ether: diethyl ether as eluent.
The products were identiﬁed by spectral data.
2.2.1.1. 5-(Dec-9-enyl)-(3H)-1,3,4-oxadiazol-2-thione, 2a. IR
(KBr, cm1): 3215 (N–H stretching), 2921 (C–H stretching),
1613 (C‚N stretching), 1165 (C‚S stretching), 1054 (C–O–
C stretching). 1H NMR (CDCl3, dH): 10.30 (1H, s, NH),
5.81 (1H, tdd, JH8CH2=6.48 HZ, JHHZ=10.31 HZ,
JHHE=17.24 HZ, CH2‚CH), 5.01 (1H, dd, JHZH=10.31
HZ, JHZHE=2.00 HZ, HZC‚CH), 4.92 (1H, dd,
JHEH=16.91 HZ, JHEHZ=2.00 HZ, HEC‚CH), 2.69 (2H, t,
J= 7.50 Hz, CH2 a to ring), 2.01 (2H, m, CH2‚CH–CH2),
1.74 (2H, m, CH2 b to ring), 1.30 (10H, br.s, (CH2)5).
13C
NMR (CDCl3, dC): 166.8, 165.4, 123.0, 122.3, 30.9, 30.8,
30.1, 29.9, 28.5, 27.1, 26.2, 24.2. MS (ESI): m/z= 262.880
found [M+Na]+, calculated [M+Na]+ = 263.146.
2.2.1.2. 5-(Heptadec-8-enyl)-(3H)-1,3,4-oxadiazol-2-thione,
2b. IR (KBr, cm1): 3218 (N–H stretching), 2925 (C–H
stretching), 1615 (C‚N stretching), 1166 (C‚S stretching)
1059 (C–O–C stretching). 1H NMR (CDCl3, dH): 10.85 (1H,
s, NH), 5.35 (2H, m, CH‚CH), 2.69 (2H, t, J= 7.58 HZ,
CH2 a to ring), 2.01 (4H, m, CH2CH‚CHCH2), 1.75
(2H, m, CH2 b to ring), 1.31 (20H, br.s, (CH2)10), 0.88 (3H,
dist.t, CH3).
13C NMR (CDCl3, dC): 165.3, 163.2, 126.0,
125.8, 35.0, 33.9, 31.0, 29.4, 28.9, 28.7, 28.0, 27.3, 26.8, 25.8,
23.7, 23.4, 23.0, 22.0, 14.0. MS (ESI) m/z= 362.231 found
[M+Na]+, calculated [M+Na]+ = 361.481.
2.2.1.3. 5-[(8Z, 11R)-11-Hydroxyheptadec-8-enyl]-(3H)-
1,3,4-oxadiazol-2-thione, 2c. IR (KBr, cm1): 3398 (O–H
stretching), 3121 (N–H stretching), 2923 (C–H stretching),
1625 (C‚N stretching), 1159 (C‚S stretching), 1056 (C–O–
C stretching). 1H NMR (CDCl3, dH): 12.34 (1H, s, NH),
5.47 (2H, m, CH‚CH), 3.68 (1H, m, CHOH), 2.68 (2H, t, J=
7.49 HZ, CH2 a to ring), 2.28(1H, m, CHOH), 2.04 (4H, m,
CH2CH‚CHCH2), 1.72 (2H, m, CH2 b to ring), 1.28 (18H,
br.s, (CH2)9), 0.88 (3H, dist.t, CH3).
13C NMR (CDCl3, dC):
168.3, 164.2, 133.2, 125.1, 72.0, 37.3, 36.6, 35.1, 31.8, 30.1,
29.7, 29.6, 29.1, 28.9, 27.2, 25.4, 24.0, 23.4, 14.2. MS (ESI)
m/z= 376.689 found [M+Na]+, calculated [M+Na]+ =
377.420.
2.2.1.4. 5-[(8R, 11Z)-8-Hydroxyheptadec-11-enyl]-(3H)-
1,3,4-oxadiazol-2-thione, 2d. IR (KBr, cm1): 3353 (O–H
stretching), 3159 (N–H stretching), 2921 (C–H stretching),
1619 (C‚N stretching), 1152 (C‚S stretching), 1051 (C–O–
C stretching). 1H NMR (CDCl3, dH): 11.56 (1H, s, NH),Please cite this article in press as: Ahmad, A. et al., Synthesis and anticance
zol-3-thione and 1,2,4-triazolo [3,4-b]-1,3,4-thiadiazine derivatives. A
j.arabjc.2014.01.0155.37 (2H, m, CH‚CH), 3.59 (1H, m, CHOH), 2.70 (2H, t,
J= 7.50 HZ, CH2 a to ring), 2.25 (1H, m, CHOH), 2.00
(4H, m, CH2CH‚CHCH2), 1.72 (2H, m, CH2 b to ring),
1.29 (18H, br.s, (CH2)9), 0.87 (3H, dist.t, CH3).
13C NMR
(CDCl3, dC): 167.5, 165.8, 133.0, 125.9, 71.9, 37.1, 36.4, 35.1,
32.8, 31.4, 30.9, 29.9, 28.2, 27.6, 26.9, 25.2, 24.6, 23.1, 14.0.
MS (ESI) m/z= 376.450 found [M+Na]+, calculated
[M+Na]+ = 377.420.
2.2.2. Synthesis of novel series of 4-amino-5-long chain alkenyl/
hydroxyalkenyl-1,2,4-triazol-3-thiones, 3(a–d)
To a solution of 0.01 mol of potassium hydroxide in 50 mL
absolute ethanol, 0.01 mol of long chain alkenyl/hydroxyalke-
nyl hydrazide, 1(a–d) and 0.013 mol of carbon disulﬁde were
added. The reaction mixture was stirred for 8 h at room tem-
perature. The reaction mixture was then diluted with 30 mL
ether and stirred for additional 1 h. The potassium salt without
further puriﬁcation was used for the next step. 0.02 Mol of
hydrazine hydrate in 20 mL water was gradually added to
the above potassium salt with constant stirring and then the
reaction mixture was reﬂuxed for 4 h. During reﬂuxing, H2S
gas released and the reaction mixture color changed to light
pink. The reaction mixture then cooled and acidiﬁed with
conc. HCl. The white solid product was separated out which
was then ﬁltered and washed with water. The solid products
3(a–d) were then air dried. The products 3(a–d) were puriﬁed
by silica gel column chromatography with petroleum ether:-
diethyl ether as eluent. The products were identiﬁed by spectral
data.
2.2.2.1. 4-Amino-5-(dec-9-enyl)-1,2,4-triazol-3-thione, 3a. IR
(KBr, cm1): 3228 (N–H stretching), 2924 (C–H stretching),
1599 (C‚N stretching), 1186 (C‚S stretching). 1H NMR
(CDCl3, dH): 11.60 (1H, s, NH), 5.79 (1H, tdd,
JH8CH2=6.70 HZ, JHHZ=10.10 HZ, JHHE=17.20 HZ, CH2-
‚CH), 5.01 (1H, dd, JHZH=10.10 HZ, JHZHE=1.30 HZ, HZ-
C‚CH), 4.94 (1H, dd, JHEH=17.20 HZ, JHEHZ=1.30 HZ,
HEC‚CH), 4.57 (2H, br.s, NH2), 2.74 (2H, t, J= 7.50 Hz,
CH2 a to ring), 2.02 (2H, m, CH2‚CH–CH2), 1.70 (2H, m,
CH2 b to ring), 1.29 (10H, br.s, (CH2)5).
13C NMR (CDCl3,
dC): 167.0, 160.5, 139.1, 121.2, 33.7, 31.8, 29.5, 29.4, 28.8,
27.2, 26.1, 24.8. MS (ESI): m/z= 276.830 found [M+Na]+,
calculated [M+Na]+ = 277.347.
2.2.2.2. 4-Amino-5-[(8Z)-heptadec-8-enyl]-1,2,4-triazol-3-thi-
one, 3b. IR (KBr, cm1): 3224 (N–H stretching), 2924 (C–H
stretching), 1595 (C‚N stretching), 1179 (C‚S stretching).
1H NMR (CDCl3, dH): 11.32 (1H, s, NH), 5.35 (2H, m,
CH‚CH), 4.55 (2H, br.s, NH2), 2.75 (2H, t, J= 7.50 HZ,
CH2 a to ring), 2.03 (4H, m, CH2CH‚CHCH2), 1.68 (2H,
m, CH2 b to ring), 1.29 (20H, br.s, (CH2)10), 0.88 (3H, dist.t,
CH3).
13C NMR (CDCl3, dC): 167.3, 165.6, 134.6, 122.1,
36.5, 34.1, 30.9, 29.2, 29.0, 28.9, 28.6, 27.4, 26.0, 25.9, 24.6,
24.1, 23.2, 22.4, 14.2. MS (ESI) m/z= 374.912 found
[M+Na]+, calculated [M+Na]+ = 375.508.
2.2.2.3. 4-Amino-5-[(8Z, 11R)-11-hydroxyheptadec-8-enyl]-
1,2,4-triazol-3-thione, 3c. IR (KBr, cm1): 3380 (O–H stretch-
ing), 3214 (N–H stretching), 2924 (C–H stretching), 1622
(C‚N stretching), 1162 (C‚S stretching). 1H NMR (CDCl3,
dH): 12.17 (1H, s, NH), 5.41 (2H, m, CH‚CH), 4.51 (2H, br.s,r activity of long chain substituted 1,3,4-oxadiazol-2-thione, 1,2,4-tria-
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4 A. Ahmad et al.NH2), 3.69 (1H, m, CHOH), 2.70 (2H, t, J= 7.51 HZ, CH2 a
to ring), 2.26 (1H, m, CHOH), 2.02 (4H, m, CH2-
CH‚CHCH2), 1.67 (2H, m, CH2 b to ring), 1.29 (18H, br.s,
(CH2)9), 0.89 (3H, dist.t, CH3).
13C NMR (CDCl3, dC):
168.0, 163.2, 135.1, 121.9, 71.9, 37.3, 36.2, 34.9, 32.8, 30.1,
29.9, 29.6, 29.1, 28.2, 28.0, 27.8, 25.4, 24.0, 13.9. MS (ESI)
m/z= 392.014 found [M+Na]+, calculated [M+Na]+
= 391.507.
2.2.2.4. 4-Amino-5-[(8R, 11Z)-8-hydroxyheptadec-11-enyl]-
1,2,4-triazol-3-thione, 3d. IR (KBr, cm1): 3376 (O–H stretch-
ing), 3217 (N–H stretching), 2921 (C–H stretching), 1619
(C‚N stretching), 1164 (C‚S stretching). 1H NMR (CDCl3,
dH): 12.09 (1H, s, NH), 5.47 (2H, m, CH‚CH), 4.56 (2H, br.s,
NH2), 3.68 (1H, m, CHOH), 2.72 (2H, t, J= 7.50 HZ, CH2 a
to ring), 2.27 (1H, m, CHOH), 2.04 (4H, m, CH2-
CH‚CHCH2), 1.69 (2H, m, CH2 b to ring), 1.28 (18H, br.s,
(CH2)9), 0.87 (3H, dist.t, CH3).
13C NMR (CDCl3, dC):
167.8, 164.4, 135.2, 122.5, 70.4, 37.2, 36.9, 34.0, 32.4, 30.1,
29.8, 29.5, 29.2, 28.7, 28.0, 27.6, 25.4, 23.5, 14.2. MS (ESI)
m/z= 392.210 found [M+Na]+, calculated [M+Na]+
= 391.507.
2.2.3. Synthesis of novel series of 3-long chain alkenyl/
hydroxyalkenyl-6-phenyl-7H-1,2,4-triazolo[3,4-b]-1,3,4-
thiadiazines, 4(a–d)
To a solution of 0.0025 mol of 4-amino-5-long chain alkenyl/
hydroxyalkenyl-1,2,4-triazol-3-thiones, 3(a–d) in 15 mL absolute
ethanol, 0.0025 mol of phenacyl bromide was added and the
reaction mixture was reﬂuxed at 90 C for 12 h on oil bath.
When all the triazole was consumed the reaction mixture
was neutralized by ammonium hydroxide. The product was ex-
tracted with dichloromethane: water. The organic layer dried
over anhydrous sodium sulfate. The solvent was evaporated
on water bath from the oily product 4(a–d). Further, the prod-
ucts 4(a–d) were puriﬁed by silica gel column chromatography
with petroleum ether: diethyl ether as eluent. The products
were identiﬁed by spectral data.
2.2.3.1. 3-(Dec-9-enyl)-6-phenyl-7H-1,2,4-triazolo[3,4-b]-
1,3,4-thiadiazine, 4a. IR (KBr, cm1): 2923 (C–H stretching),
1604 (C‚N stretching), 1125 (C–N stretching), 652 (C–S–C
stretching). 1H NMR (CDCl3, dH): 7.55–7.39 (5H, m, ArH),
5.78 (1H, tdd, JH8CH2=6.72 HZ, JHHZ ¼ 10:00 HZ, JHHE ¼
17:24 HZ, CH2‚CH), 5.01 (1H, dd, JHZH ¼ 10:12 HZ,
JHZHE ¼ 1:35 HZ, HZC‚CH), 4.94 (1H, dd, JHEH ¼ 17:23
HZ, JHEHZ ¼ 1:34 HZ, HEC‚CH), 4.12 (2H, s, CH2 ring),
2.75 (2H, t, J= 7.50 Hz, CH2 a to ring), 2.04 (2H, m, CH2-
‚CH–CH2), 1.69 (2H, m, CH2 b to ring), 1.28 (10H, br.s,
(CH2)5).
13C NMR (CDCl3, dC): 168.1, 165.4, 160.8, 134.8,
132.9, 132.5, 131.1, 130.5, 124.8, 122.5, 115.4, 36.2, 34.2, 33.9,
32.8, 32.1, 31.7, 30.9, 29.4, 25.0. MS (ESI): m/z= 378.041
found [M+Na]+, calculated [M+Na]+ = 377.459.
2.2.3.2. 3-[(8Z)-Heptadec-8-enyl]-6-phenyl-7H-1,2,4-triazol-
o[3,4-b]-1,3,4-thiadiazine, 4b. IR (KBr, cm1): 2926 (C–H
stretching), 1599 (C‚N stretching), 1120 (C–N stretching),
660 (C–S–C stretching). 1H NMR (CDCl3, dH): 7.62–7.40
(5H, m, ArH), 5.35 (2H, m, CH‚CH), 4.09 (2H, s, CH2 ring),
2.67 (2H, t, J= 7.54 HZ, CH2 a to ring), 2.03 (4H, m, CH2-
CH‚CHCH2), 1.64 (2H, m, CH2 b to ring), 1.25 (20H, br.s,Please cite this article in press as: Ahmad, A. et al., Synthesis and anticance
zol-3-thione and 1,2,4-triazolo [3,4-b]-1,3,4-thiadiazine derivatives. A
j.arabjc.2014.01.015(CH2)10), 0.87 (3H, dist.t, CH3).
13C NMR (CDCl3, dC): 168.3,
165.6, 160.5, 134.5, 132.5, 132.0, 131.5, 130.8, 129.7, 125.0,
122.1, 35.5, 34.0, 32.5, 30.5, 29.0, 28.9, 28.4, 28.0, 27.2, 26.6,
25.5, 24.4, 24.0, 23.1, 21.4, 14.3.MS (ESI)m/z= 474.971 found
[M+Na]+, calculated [M+Na]+ = 475.620.
2.2.3.3. 3-[(8Z, 11R)-11-Hydroxyheptadec-8-enyl]-6-phenyl-
7H-1,2,4-triazolo[3,4-b]-1,3,4-thiadiazine, 4c. IR (KBr, cm1):
3360 (O–H stretching), 2922 (C–H stretching), 1613 (C‚N
stretching), 1115 (C–N stretching), 665 (C–S–C stretching). 1H
NMR (CDCl3, dH): 7.60–7.35 (5H, m, ArH), 5.40 (2H, m,
CH‚CH), 4.10 (2H, s, CH2 ring), 3.62 (1H, m, CHOH), 2.72
(2H, t, J= 7.50 HZ, CH2 a to ring), 2.28 (1H, m, CHOH),
2.01 (4H, m, CH2CH‚CHCH2), 1.68 (2H, m, CH2 b to ring),
1.29 (18H, br.s, (CH2)9), 0.87 (3H, dist.t, CH3).
13C NMR
(CDCl3, dC): 167.0, 164.1, 163.8, 135.1, 132.7, 132.2, 131.4,
130.1, 123.4, 123.0, 121.9, 112.8, 36.3, 34.8, 33.9, 32.4, 30.3,
29.9, 29.5, 29.2, 28.7, 28.3, 27.8, 26.6, 24.7, 24.4, 14.2. MS
(ESI) m/z= 492.106 found [M+Na]+, calculated [M+Na]+
= 491.619.
2.2.3.4. 3-[(8R, 11Z)-8-Hydroxyheptadec-11-enyl]-6-phenyl-
7H-1,2,4-triazolo[3,4-b]-1,3,4-thiadiazine, 4d. IR (KBr, cm1):
3382 (O–H stretching), 2924 (C–H stretching), 1615 (C‚N
stretching), 1122 (C–N stretching), 667 (C–S–C stretching). 1H
NMR (CDCl3, dH): 7.58–7.35 (5H, m, ArH), 5.37 (2H, m,
CH‚CH), 4.19 (2H, s, CH2 ring), 3.64 (1H, m, CHOH), 2.69
(2H, t, J= 7.50 HZ, CH2 a to ring), 2.28 (1H, m, CHOH),
2.04 (4H, m, CH2CH‚CHCH2), 1.65 (2H, m, CH2 b to ring),
1.28 (18H, br.s, (CH2)9), 0.87 (3H, dist.t, CH3).
13C NMR
(CDCl3, dC): 167.8, 166.2, 164.4, 133.2, 132.6, 131.9, 131.5,
130.6, 129.6, 123.1, 122.5, 70.2, 37.1, 36.5, 32.8, 32.6, 30.3,
29.8, 29.4, 29.1, 28.5, 28.0, 27.8, 27.2, 25.8, 23.9, 14.1. MS
(ESI) m/z= 492.110 found [M+Na]+, calculated [M+Na]+
= 491.619.
2.3. In vitro anticancer activity
2.3.1. Blood peripheral mononuclear cell isolation
Fresh blood (20–15 mL) was kindly provided by blood bank,
Jawaharlal Nehru Medical College, Aligarh Muslim Univer-
sity, Aligarh. The blood sample was diluted with the same vol-
ume of phosphate buffer saline (PBS). After that, the diluted
blood sample was carefully layered on Ficoll-Histopaque (Sig-
ma Aldrich, USA). The mixture was centrifuged at 400g for
30 min at 20–22 C. The undisturbed lymphocyte layer was
carefully transferred out. The lymphocyte was washed and pel-
leted down with three volumes of PBS twice and resuspended
RPMI-1640 media (Sigma Aldrich, USA) with antibiotic and
antimycotic solution (Sigma Aldrich, USA) 10%, v/v fetal calf
serum (FCS) (Sigma Aldrich, USA). Cell counting was per-
formed to determine the PBMC cell number with equal volume
of trypan blue (Yeap et al., 2007; Yang et al., 1999).
2.3.2. MTT assay
The PBMCs/HeLa/Hep3 B/MCF 7 cell lines were maintained
in RPMI 1640 (Sigma Aldrich) culture medium supplemented
with 10% heat-inactivated fetal calf serum and antibiotic anti-
mycotic solution (Sigma Aldrich). The cells were plated at a
density of 5 · 103 cells per well in a 96-well plate, and culturedr activity of long chain substituted 1,3,4-oxadiazol-2-thione, 1,2,4-tria-
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Scheme 2 Ring closure synthetic pathway of novel series of
3-long chain alkenyl/hydroxyalkenyl-6-phenyl-7H-1,2,4-triazol-
o[3,4-b]-1,3,4-thiadiazines, 4(a–d). Reagents and conditions: (i)
PhCOCH2Br, EtOH, reﬂux (90 C), 12 h, neutralization with
NH4OH.
Synthesis and anticancer activity of long chain substituted 1,3,4-oxadiazol-2-thione 5for 24 h at 37 C. The cells were subsequently exposed to
drugs. The plates were incubated for 48 h, and cell prolifera-
tion was measured by adding 20 lL of MTT (Sigma Aldrich)
dye (5 mg/mL in phosphate-buffered saline) per well. The
plates were incubated for a further 4 h at 37 C in a humidiﬁed
chamber containing 5% CO2. Formazan crystals formed due
to the reduction of dye by viable cells in each well were dis-
solved in 150 lL dimethyl sulfoxide, and absorbance was read
at 570 nm. The absorption values were expressed as the cell
viability (%), according to the control group as 100%. The
concentration required for 50% inhibition of cell viability
(IC50) was calculated using the software ‘‘Prism 3.0’’.
3. Result and discussion
3.1. Chemistry
Earlier in our laboratory it has been reported that some other
1,3,4-oxadiazoles substituted with fatty acid chain possess
antibacterial activity (Banday et al., 2010). Due to the biolog-
ical importance of heterocyclic FA analogs, synthesis of target
compounds 2(a–d), 3(a–d), 4(a–d) and evaluation of anticancer
activity were reported in this paper. All reactions are outlined
in Schemes 1 and 2. The physicochemical parameters of all the
newly synthesized compounds are tabulated in Table 1. Three
novel series of oxadiazolthiones, 2(a–d); triazolthiones, 3(a–d)
and triazolothiadizines, 4(a–d) were obtained from the corre-
sponding unsaturated/hydroxy unsaturated FAHs, 1(a–d).
These FAHs were used as starting material which was previ-
ously synthesized in our research laboratory from the corre-
sponding FAs. The cyclization reaction of carbon disulﬁde
with FAHs gives a novel series of 5-long chain alkenyl/hydrox-
yalkenyl-1,3,4-oxadiazol-2-thiones, 2(a–d). 4-Amino-5-long
chain alkenyl/hydroxyalkenyl-1,2,4-triazol-3-thiones, 3(a–d)
were obtained by reaction of carbon disulﬁde and FAHs on
treatment with hydrazine hydrate. Furthermore, biheterocyclic
derivatives of FAs i.e. 4-amino-5-long chain alkenyl/hydroxy
alkenyl-6-phenyl-7H-1,2,4-triazolo[3,4-b]-1,3,4-thiadiazines,
4(a–d) were synthesized from corresponding compound 3(a–d)
and phenacyl bromide by ring closure reaction. The 1,3,4-
oxadiazole-2-thiones and 1,2,4-triazol-3-thiones may exist in
thiol–thione tautomeric forms, but in solid state thione form
dominates. Such observations are also reported in theRCON
1(a
NN
O SHR
NHN
O S
R
2(a-d)
(i)
Scheme 1 Synthetic pathway for two novel series of 5-long cha
4-amino-5-long chain alkenyl/hydroxyalkenyl-1,2,4-triazol-3-thiones, 3
(i) CS2, KOH, EtOH, reﬂux (80–90 C), 8 h, acidiﬁcation with HCl up
Et2O, stir, room temperature, 1 h. (iv) N2H4.2H2O, reﬂux (90 C), 4 h
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j.arabjc.2014.01.015literature (Banday and Rauf, 2009). Structure of compound
2b appeared in the literature also, (Toliwal et al., 2009) but
without spectral data. All reactions were monitored by using
thin layer chromatography (TLC) time by time. Products were
puriﬁed by column chromatography. The structure of all the
newly synthesized compounds was determined on the basis
of their IR, 1H NMR, 13C NMR and mass spectral data. Char-
acteristic [M+Na]+ ion peaks were observed for all the com-
pounds under study. A detailed spectral description for
compound 2a, 3a and 4a is discussed below.
IR spectrum of compound 5-(dec-9-enyl)-(3H)-1,3,4-oxa-
diazol-2-thione, 2a revealed characteristic bands at 3215 cm1
for N–H stretching, 2921 cm1 for C–H stretching and the
detection of C‚N stretching band at 1613 cm1, C‚S stretch-
ing band at 1165 cm1 and C–O–C stretching band at 1054 cm1
for evidence of ring closure of 1,3,4-oxadiazol-2-thione ring. No
peak was observed around 2600–2550 cm1 for the thiol
group, further conﬁrmed the structure of compound 2a. In
the 1H NMR spectrum of compound 2a, characteristic peak
was observed for N–H proton at d 10.30 as singlet, in addition
to peaks of FA chains. The 13C NMR characteristic peaks for
compound 2a were observed at d 166.8, 165.4, 123.0 and 122.3.
Further evidence for the formation of 2a was obtained by
recording the mass spectrum which showed the [M+Na]+
ion peak at m/z 262.880. Similarly, the structures of com-
pounds 2(b–d) were conﬁrmed from their spectral data given
in spectral section.HNH2
-d)
NN
N SHR
NHN
N
SR
NH2 NH2
3(a-d)
(ii), (iii), (iv)
in alkenyl/hydroxyalkenyl-1,3-4-oxadiazol-2-thiones, 2(a–d) and
(a–d) showing thiol-thione tautomerism. Reagents and conditions:
to pH 3. (ii) CS2, KOH, EtOH, stir, room temperature, 8 h. (iii)
, acidiﬁcation with HCl up to pH 3.
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Table 1 Physico-chemical properties of all the newly synthesized compounds, 2(a–d), 3(a–d) and 4(a–d).
S.No. Compound code R Molecular formula Physical state M.P. (C) % Yield Molec. wt.
1 2a HE
HZ
7
C12H20N2OS White powder 86–88 90 240.157
2 3a HE
HZ
7
C12H22N4S White powder 84–86 90 254.358
3 4a HE
HZ
7
C20H26N4S Brown sticky liquid - 65 354.470
4 2b
7 6
C19H34N2OS White powder 87–89 80 338.492
5 3b
7 6
C19H36N4S White powder 76–77 85 352.519
6 4b
7 6
C27H40N4S Brown sticky liquid - 62 452.631
7 2c
5 6
OH
C19H34N2O2S Yellow solid 76–78 80 354.431
8 3c
5 6
OH
C19H36N4OS Yellow solid 62–64 78 368.518
9 4c
5 6
OH
C27H40N4OS Brown sticky liquid - 60 468.630
10 2d
OH
4 2 6
C19H34N2O2S Yellow solid 75–76 84 354.431
11 3d
OH
4 2 6
C19H36N4OS Yellow solid 64–66 80 368.518
12 4d
OH
4 2 6
C27H40N4OS Brown sticky liquid - 60 468.630
M.P.: Melting point.
6 A. Ahmad et al.The structure of compound 4-amino-5-(dec-9-enyl)-1,2,4-
triazol-3-thione, 3a was conﬁrmed by the appearance of
absorption bands at 3228 cm1 for N–H stretching,
2924 cm1 for C–H stretching, 1599 cm1 for C‚N stretching
and for C‚S stretching, the absorption band appeared at
1186 cm1. No peak was observed around 2600–2550 cm1Please cite this article in press as: Ahmad, A. et al., Synthesis and anticance
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j.arabjc.2014.01.015for the thiol group, further conﬁrmed the thione structure of
compound 3a. The 1H NMR characteristic peaks were
observed at d 11.60 as singlet for N–H proton, d 4.57 as broad
singlet for NH2 protons. The
13C NMR characteristic peaks
for compound 3a were observed at d 167.0, 160.5, 139.1 and
121.2. In addition, evidence for the formation of 3a wasr activity of long chain substituted 1,3,4-oxadiazol-2-thione, 1,2,4-tria-
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Figure 1 Dose–response effect of all the synthesized compounds
2(a–d), 3(a–d) and 4(a–d) on cell-viability of Hep3 B, MCF 7,
HeLa and PBMCs. Data expressed here are mean ± standard
deviation of three independent experiments.
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zol-3-thione and 1,2,4-triazolo [3,4-b]-1,3,4-thiadiazine derivatives. A
j.arabjc.2014.01.015obtained by recording the mass spectrum which showed the
[M+Na]+ ion peak at m/z 276.830. Similarly, the structures
of compounds 3(b–d) were conﬁrmed from their spectral data
given in spectral section.
The structure of compound 3-(dec-9-enyl)-6-phenyl-7H-
1,2,4-triazolo[3,4-b]-1,3,4-thiadiazine, 4a was conﬁrmed by
the appearance of absorption bands at 2923 cm1 for C–H
stretching, 1604 cm1 for C‚N stretching, 1125 cm1 for
C–N stretching, 652 cm1 for C–S–C stretching. The disap-
pearance of absorption peaks for N–H and C‚S stretching
further conﬁrmed the structure of compound 4a. The 1H
NMR characteristic peaks were observed at d 7.55–7.39 as
multiplet for ﬁve aromatic protons, d 4.12 as singlet for two
ring protons. The disappearance of 1H NMR peak for N–H
proton further conﬁrmed the structure of compound 4a. The
13C NMR characteristic peaks for compound 4a were observed
at d 168.1, 165.4, 160.8, 134.8, 132.9, 132.5, 131.1, 130.5, 124.8,
122.5, 115.4 and 36.2. Conﬁrmation for the formation of 4a
was also obtained by recording the mass spectrum which
showed the [M+Na]+ ion peak at m/z 378.041. Similarly,
the structures of compounds 4(b–d) were conﬁrmed from their
spectral data given in spectral section.
3.2. In vitro cytotoxic evaluation and structure–activity
relationship
In vitro cytotoxicity of all the newly synthesized compounds
(2a–d), (3a–d) and (4a–d) was measured by MTT [3-(4,5-dim-
ethylthiazolyl-2)-2,5-diphenyltetrazolium bromide] assay
against a panel of three different human cancer cell lines
namely; human hepatocellular carcinoma (Hep3 B), human
breast adenocarcinoma (MCF 7) and human cervical carci-
noma (HeLa). These cell lines are procured from Cell Reposi-
tory–National Centre for Cell Science, Pune (India). Normal
human cells (PBMCs) were also used for the determination
of cytotoxicity of synthesized compounds. The MTT assay is
a colorimetric assay for measuring the cellular growth that
reduces the tetrazolium yellow dye MTT, to its insoluble for-
mazan (purple color) by mitochondrial dehydrogenases of liv-
ing cells. MTT is used to determine the cytotoxicity of
potential drugs and other toxic compounds. The insoluble pur-
ple formazan product is dissolved into a colored solution by
the addition of a suitable solvent. At certain wavelength, the
absorbance of this colored solution can be measured. The po-
tency of the drug in causing cell death can be concluded
through the production of dose–response curves when the pur-
ple formazan was produced by untreated control cells. Curves
of dose-dependent effects of (2a–d), (3a–d) and (4a–d) on cell
viability of different human cancer cell lines (Hep3 B, MCF
7, HeLa) and normal human cells (PBMCs) are displayed in
Fig. 1. Doxorubicin and 5-ﬂuorouracil were used as standard
drugs. Experiment was performed in a triplicate. For each of
the tested drug IC50 was calculated and the results are summa-
rized in Table 2. Experiments revealed that there was a sub-
stantial increase in cytotoxicity in cancer cell lines with
increasing exposure to drug concentration i.e. showing low
IC50 values and our in-house synthesized drugs were not
showing marked effects on normal human cells (PBMCs) i.e.
showing high IC50 values. None of the synthesized compounds
showed cytotoxicity to normal human cells (PBMCs). The
present study showed that among the three human cancer cellr activity of long chain substituted 1,3,4-oxadiazol-2-thione, 1,2,4-tria-
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Table 2 Showing anticancer data (IC50 values in lM) of all the synthesized drugs and standard drugs against three different human
cancer cell lines and normal human cells.
S. No. Compound codes Hep3 B MCF 7 HeLa PBMC
1 2a 08.94 ± 2.5 13.60 ± 2.5 11.90 ± 1.3 35.32 ± 3.1
2 2b 16.42 ± 1.5 19.00 ± 2.5 17.60 ± 2.3 39.12 ± 1.7
3 2c 09.00 ± 1.6 15.90 ± 1.6 12.90 ± 1.3 45.42 ± 4.1
4 2d 10.10 ± 2.6 16.83 ± 2.6 13.30 ± 3.3 41.38 ± 2.5
5 3a 09.20 ± 0.8 14.00 ± 0.6 11.10 ± 2.1 39.12 ± 1.6
6 3b 16.60 ± 1.2 19.90 ± 0.7 18.80 ± 1.3 43.83 ± 1.9
7 3c 09.48 ± 1.4 13.20 ± 0.5 16.20 ± 2.4 33.57 ± 2.3
8 3d 09.96 ± 2.8 14.50 ± 1.6 15.82 ± 3.1 35.25 ± 1.9
9 4a 07.40 ± 2.2 10.30 ± 2.7 08.01 ± 1.3 32.78 ± 2.9
10 4b 09.49 ± 1.5 11.27 ± 2.4 10.03 ± 1.7 >50
11 4c 06.50 ± 2.4 08.59 ± 1.5 08.83 ± 1.4 >50
12 4d 07.36 ± 1.6 08.80 ± 2.1 06.00 ± 3.1 39.12 ± 3.1
Doxoa 02.35 ± 1.2 03.12 ± 1.7 03.56 ± 2.7 09.23 ± 2.6
5-Fub 03.54 ± 2.1 04.12 ± 2.3 02.78 ± 2.6 08.91 ± 1.9
Standard drugs used for reference.
a Doxorubicin.
b 5-Fluorouracil.
Synthesis and anticancer activity of long chain substituted 1,3,4-oxadiazol-2-thione 9lines tested, Hep3 B cells were found to be sensitive to all the
tested compounds while HeLa and MCF 7 cells were found
to be sensitive to some selected compounds. The obtained re-
sults revealed that compound 2a, 2c, 2d, 3a, 3c, 3d, 4a, 4b,
4c and 4d showed remarkable inhibitory activities against dif-
ferent human cancer cell lines and were also comparable to the
standard drugs.
On the basis of structure–activity relationships, it could be
concluded that 1,2,4-triazole fused with the 1,3,4-thiadiazine
ring was found to have better antitumor activity than those
of 1,2,4-triazoles and 1,3,4-oxadiazoles. The structural activity
study also shows that anticancer activity is also dependent on
the nature of alkenyl/hydroxyalkenyl FA chain. From IC50 val-
ues a number of correlations can be made. It is apparent from
the IC50 values that, all the tested compounds show moderate
to good cytotoxicity against different human cancer cell lines.
For C10 terminal alkenyl FA chain residue which is substituted
at 5-position of 1,3,4-oxadiazol-2-thione (compound, 2a) and
at 3-position of 1,2,4-triazol-3-thione (compound, 3a) leads to
a remarkable increase in potency against human hepatocellular
carcinoma cells (IC50 value of 08.94 ± 2.5 and 09.20 ±
1.5 lM, respectively). Incorporation of the 1,3,4-thiadiazine
ring with the 1,2,4-triazole ring having C10 terminal alkenyl
FA chain residue at 3-position of 1,2,4-triazolo-[3,4-b]-1,3,4-
thiadiazine (compound, 4a) leads to an increase in cytotoxicity
against all the three human cancer cell lines; IC50 values of
07.40 ± 2.2 lM (against Hep3 B cells), 10.30 ± 2.7 lM
(against MCF 7 cells), 08.01 ± 1.3 lM (against HeLa cells). In-
crease in carbon chain length (C17) of internal alkenyl FA chain
residue at 5-position of 1,3,4-oxadiazol-2-thione (compound,
2b) and at 3-position of 1,2,4-triazol-3-thione (compound, 3b)
leads to high IC50 values i.e. IC50 value was above 16.42 lM
against all the three tested human cancer cells. In case of
1,2,4-triazolo-[3,4-b]-1,3,4-thiadiazine ring system, even the
chain length of the internal alkenyl substituent at 3-position
(compound, 4b) was increased (C17) still it displayed good anti-
tumor activity against all the three cancer cell lines (IC50 value
of 09.49 ± 1.5 lM against Hep3 B cells, 11.27 ± 2.4 lM
against MCF 7 cells and 10.03 ± 1.7 lM against HeLa cells),Please cite this article in press as: Ahmad, A. et al., Synthesis and anticance
zol-3-thione and 1,2,4-triazolo [3,4-b]-1,3,4-thiadiazine derivatives. A
j.arabjc.2014.01.015this may be due to the fused ring system. Presence of the
hydroxyl group on alkenyl FA chain residue which is attached
to 1,3,4-oxadiazol-2-thione at 5-position (compound, 2c and
2d) was responsible for an increase in potency against hepato-
cellular carcinoma cells (IC50 values of 09.00 ± 1.6 and
10.10 ± 2.6 lM, respectively). Also, in case of 1,2,4-triazole,
the presence of the hydroxyl group on the alkenyl FA chain res-
idue at 3-position was responsible for increased cytotoxicity of
compound 3c and 3d against Hep3 B cells (IC50 value of
09.48 ± 1.4 and 09.96 ± 2.8 lM, respectively). For compound
4c and 4d, there were two reasons for an increase in potency
against all the three cancer cell lines: the presence of the hydro-
xyl group on the alkenyl fatty acid substituent and the other
was the presence of fused ring system i.e. incorporation of thi-
adiazine with the triazole ring (IC50 values of 06.50 ± 2.4 lM
against Hep3 B cells, 08.59 ± 1.5 lM against MCF 7 cells,
08.83 ± 1.4 lM against HeLa cells and 07.36 ± 1.6 lM
against Hep3 B cells, 08.80 ± 2.1 lM against MCF 7 cells,
06.00 ± 3.1 lM against HeLa cells, respectively). These initial
ﬁndings lead to further derivatization of heterocyclic FAs.
Investigation of feasible mechanism of preventing cancer cell
lines propagation is in progress.4. Conclusion
We described here the synthesis of novel heterocyclic fatty acid
analogs and in vitro anticancer activity evaluation of synthe-
sized compounds against different human cancer cell lines
and PBMCs by MTT assay. Anticancer activity results re-
vealed that the synthesized compounds are non-toxic to the
normal human cells and can be used safely for the treatment
of cancer without damaging normal cells. The results of cyto-
toxic study also show that, all compounds possess moderate to
good activity but compounds 4c and 4d were the most prom-
ising cytotoxic agent with IC50 values below 08.83 ± 1.4 lM
against all the three tested human cancer cells (Hep3 B,
MCF 7, HeLa cells) due to the presence of the hydroxyl group
on FA chain and fused ring system (triazolothiadiaziner activity of long chain substituted 1,3,4-oxadiazol-2-thione, 1,2,4-tria-
rabian Journal of Chemistry (2014), http://dx.doi.org/10.1016/
10 A. Ahmad et al.nucleus). From this study, it can be concluded that the potency
of drugs depends on the nature of FA chain and the heterocy-
clic ring system. From these studies, it is comprehensible that
further derivatization of different heterocyclic analogs of fatty
acids can serve as new templates for antitumor chemotherapy
and could probably lead to more active molecules in the area
of cancer chemotherapy.Acknowledgments
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